Aquestive Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated products to address unmet medical needs. Its product candidates include AQST-108, AQST-305, AQST-109, AQST-119, and AQST-120. Its AQST-108 is designed to provide quick relief of symptoms associated with an acute migraine. AQST-305 is designed to provide relief of symptoms associated with Parkinson's disease and other indications. AQST-109 is designed to deliver epinephrine via an oral cavity film to treat anaphylaxis. AQST-119 is designed to deliver tadalafil via an oral cavity film for the treatment of erectile dysfunction. AQST-120 is designed to deliver octreotide via an oral cavity film for the treatment of acromegaly and neuroendocrine tumors. The Company's products are developed using its PharmFilm technology.